Holbrook Kohrt
Academic Appointments
- Assistant Professor - Med Center Line, Medicine - Oncology
Key Documents
Contact Information
-
Clinical Offices
Stanford Cancer Center 875 Blake Wilbur Dr MC 5821 Stanford, CA 94305 Tel Work (650) 723-6661 Fax (650) 723-9113
Professional Overview
Clinical Focus
- Cancer> Lymphoma
- Oncology
Professional Education
| Residency: | Stanford University Hospital - Internal Medicine CA (2007) |
| Internship: | Stanford University Hospital - Internal Medicine CA (2006) |
| Fellowship: | Stanford University - Hematology & Oncology CA (2011) |
| Board Certification: | General Internal Medicine, American Board of Internal Medicine (2008) |
| Medical Education: | Stanford University School of Medicine, CA USA (2005) |
| PhD: | Stanford University, Clinical Trial Design & Tumor Immunology (2011) |
Scientific Focus
Current Research Interests
Specific areas of active research include:
1. Immune Cell Allotransplantation for Curing Cancer: To develop novel vaccine strategies which induce tumor antigen specific immunity prior to infusing the donor inoculum and improve graft-versus-tumor reactions without exacerbation of graft-versus-host disease.
2. Augmenting Antibody Therapy for Curing Cancer: To identify and develop immunomodulatory antibodies targeting immune effector cells subsets, such as natural killer cells, which enhance the anti-tumor activity of tumor-targeting antibodies.
Clinical Trials
- Recruiting A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab
- Recruiting A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers
- Recruiting Study of the Safety and Pharmacokinetics of MPDL3280A Administered Intravenously As a Single Agent to Patients With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies
- Recruiting Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
- Not Recruiting Phase I/II of Azacitidine + Lenalidomide for Previously Untreated Elderly Patients With Acute Myeloid Leukemia
Publications
- Adoptive cell therapy for lymphoma with CD4 T cells depleted of CD137-expressing regulatory T cells. Cancer Res. 2012; (5): 1239-47
- CD137 is expressed in follicular dendritic cell tumors and in classical Hodgkin and T-cell lymphomas: diagnostic and therapeutic implications. Am J Pathol. 2012; (3): 795-803
- Co-transplantation of pure blood stem cells with antigen-specific but not bulk T cells augments functional immunity. Proc Natl Acad Sci U S A. 2012; (15): 5820-5
- Combination strategies to enhance antitumor ADCC. Immunotherapy. 2012; (5): 511-27
- Long-term outcome of patients with metastatic breast cancer treated with high-dose chemotherapy and transplantation of purified autologous hematopoietic stem cells. Biol Blood Marrow Transplant. 2012; (1): 125-33
- Rapid development of exhaustion and down-regulation of eomesodermin limit the antitumor activity of adoptively transferred murine natural killer cells. Blood. 2012; (24): 5758-68
Help
Trial Administration